FINWIRES · TerminalLIVE
FINWIRES

Utz Brands' Underlying Growth Remains Strong, RBC Capital Markets Says

作者

-- Utz Brands' (UTZ) quarter-to-date trends appear soft but underlying growth remains solid, driven by distribution gains, innovation, and California expansion momentum, RBC Capital Markets said in a note Thursday.

Management is optimistic that the company's new products will support topline growth and that the company is well-covered for most of the year on fuel, agricultural commodities, and freight, easing inflationary concerns, according to the note.

Full-year guidance for the salty snacks category still assumes an approximately flat growth, which analysts said is appropriate given the noisy Q1 and consumer environment.

Following the roughly in-line Q1 results and reaffirmed guidance, the brokerage said it is adjusting its 2026 estimates to reflect organic sales growth of 2.5%, EBITDA growth of 6%, and an EPS decline of 4.1%.

RBC Capital Markets maintained its outperform rating on the stock, with a price target of $15.

Shares of Utz Brands were down 5% in Thursday trading.

Price: $7.88, Change: $-0.42, Percent Change: -5.06%

相關文章

Sectors

產業動態:消費股午後小幅走低

週四下午晚些時候,消費性股票小幅下跌,道富消費必需品精選行業SPDR ETF (XLP) 和道富非必需消費品精選行業SPDR ETF (XLY) 均下跌0.1%。 公司新聞方面,Tapestry (TPR) 在公佈第三季業績超出預期後,上調了2026財年業績預期,但對其旗下Kate Spade品牌第四季的銷售預期較為保守。受此影響,該公司股價下跌超過13%。 Shake Shack (SHAK) 股價暴跌28%,此前該公司公佈的第一季業績不如華爾街預期。 Planet Fitness (PLNT) 股價暴跌32%,此前該公司因第一季新增會員數量低於預期而下調了全年業績預期。 麥當勞 (MCD) 公佈的第一季業績好於預期,儘管該公司稱其面臨「充滿挑戰」的市場環境,但同店銷售額的反彈幅度仍超過市場預期。其股價上漲了0.3%。

$MCD$PLNT$SHAK$TPR
Sectors

板塊動態:醫療保健股午後走軟

週四下午晚些時候,醫療保健類股下跌,紐約證券交易所醫療保健指數下跌0.6%,道富醫療保健精選行業SPDR ETF (XLV)下跌0.7%。 iShares生物技術ETF (IBB)下跌2.2%。 在公司新聞方面,根據路透社週四報導,Entrada Therapeutics (TRDA) 的股價暴跌57%,此前該公司用於治療杜氏肌肉營養不良症兒童的藥物在早期至中期臨床試驗中未達到分析師預期。 Iovance Biotherapeutics (IOVA) 的股價下跌超過13%,此前該公司第一季虧損收窄幅度小於預期,且營收不及預期。 Harmony Biosciences (HRMY) 的股價下跌5.5%,此前該公司第一季獲利和營收均低於分析師預期。 Catalyst Pharmaceuticals (CPRX) 股價上漲 2.1%,此前該公司同意被 Angelini Pharma 以約 41 億美元的股權價值收購。該公司還表示,已與 Hetero Labs 達成和解協議,以解決有關 Firdapse 擬推出的仿製藥版本的專利訴訟。

$CPRX$HRMY$IOVA$TRDA
Research

——國家銀行將Cascades的目標股價從14加元下調至13加元,維持該板塊「與大盤持平」的評級,並指出第一季業績與下調後的預期一致,第二季度預期疲軟,之後將出現復甦,資產出售工作將在第三季度完成。國家銀行表示,第一季業績預計與下調後的預期相符,第二季預期疲軟,之後將出現復甦,資產出售工作將在第三季完成。

Price: $10.72, Change: $-0.23, Percent Change: -2.10%

$CAS.TO